AbbVie Increases US Manufacturing, But Says It’s Not Because Of Tariffs

CEO Robert Michael said AbbVie is positioned strongly to handle current and potentially upcoming tariffs, while committing $10bn to increased US manufacturing sites.

AbbVie exterior
AbbVie's Skyrizi and Rinvoq continued their steep sales trajectories • Source: Alamy

During its first quarter sales and earnings call on 25 April, AbbVie CEO Robert Michael expressed confidence that the company can weather the current tariffs introduced by the Trump Administration as well as potential upcoming “sectoral tariffs” that could be imposed on the biopharmaceutical industry, but noted AbbVie’s current financial guidance does not account for the possible impact of additional tariffs.

Key Takeaways
  • AbbVie CEO Robert Michael said the company is not trying to project the impact of possible future tariffs on imports.

“To the extent there is an impact, we believe it would be in line with our peers given that AbbVie...

More from Earnings

More from Therapy Areas

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?